AstraZeneca Plc has issued fresh data from its US Phase 3 trial of a Covid-19 vaccine developed jointly with Oxford University (AZD1222) showing an efficacy rate of 76% against symptomatic disease. The primary efficacy analysis included the accrual of 190 symptomatic cases of Covid-19 from the 32,449 trial participants. This represents an additional 49 cases as compared with an interim analysis of the trial which was published on 22 March and showed an efficacy rate of 79%.
